Bioorg Med Chem Lett 2002 Jan;12(2):233-5
Novartis Pharma AG, Arthritis & Bone Metabolism, CH-4002 Basel, Switzerland.
The synthesis of a 6,8-disubstituted 1,7-naphthyridine 1 and its characterization as a potent and selective phosphodiesterase type 4D inhibitor (IC(50)=1.5nM) are described. The compound inhibited TNFalpha-release from human peripheral blood mononuclear cells and was orally active in a model of adjuvant-induced arthritis in rats.